A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts

Area of Science:

• Oncology
• Molecular Biology
• Drug Delivery

Background:

• E2F-1 is a crucial transcription factor for cell growth and differentiation, making it a target for cancer therapy.
• Tumors dependent on E2F-1 present an opportunity for targeted anticancer drug development.
• A peptide identified through phage display binds to E2F-1 consensus sequences and exhibits cytotoxicity.

Purpose of the Study:

• To evaluate the therapeutic potential of an E2F-1-binding peptide coupled to penetratin (PEP).
• To assess the efficacy and stability of PEP, and its delivery using PEGylated liposomes (PL-PEP) in prostate cancer models.

Main Methods:

• Peptide isolation and characterization based on E2F-1 binding.
• Cytotoxicity assays on various cancer cell lines, including prostate cancer.
• In vitro and in vivo studies using PEP and PL-PEP in prostate cancer models (cell lines and patient-derived xenografts).
• Assessment of PEP stability in serum and toxicity of PL-PEP in mice.

Main Results:

• The peptide demonstrated significant cytotoxicity against a broad spectrum of cancer cell lines.
• PEP showed efficacy against prostate cancer cell lines and a patient-derived metastatic sample.
• PEGylated liposome encapsulation improved PEP stability and in vivo efficacy.
• PL-PEP treatment led to significant tumor regression in mice with human prostate tumors (Du-145) without notable toxicity.

Conclusions:

• Liposome-encapsulated PEP is a promising anticancer agent for E2F-1-dependent tumors.
• PL-PEP exhibits potential as a standalone therapy or in combination with DNA synthesis inhibitors.
• This approach offers a targeted strategy for treating prostate cancer and potentially other malignancies.